Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Med (New York, N.Y.)|August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trialsAlberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Cancer|July 7, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 studyMiguel-Ángel Berciano-Guerrero, Elisabeth Pérez-Ruiz, Ainara Soria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
The Lancet Regional Health. Europe|November 12, 2024
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational studyOriol Mirallas, Berta Martin-Cullell, Víctor Navarro, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 28, 2025
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801Enrique Espinosa, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2025
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence studyMichael Weichenthal, Eva Ellebaek, Joanna Mangana, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Med (New York, N.Y.)|August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trialsAlberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Cancer|July 7, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 studyMiguel-Ángel Berciano-Guerrero, Elisabeth Pérez-Ruiz, Ainara Soria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
The Lancet Regional Health. Europe|November 12, 2024
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational studyOriol Mirallas, Berta Martin-Cullell, Víctor Navarro, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 28, 2025
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801Enrique Espinosa, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2025
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence studyMichael Weichenthal, Eva Ellebaek, Joanna Mangana, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 8